secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0000950170-24-053197
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome Q1 net product revenue $75M (+160% YoY); net loss $68.4M; pipeline milestones on track
--------------------------------------------------------------------------------

- Auvelity net sales $53.4M (+240% YoY); Sunosi net revenue $21.6M (+64% YoY).
- Net loss $68.4M ($1.44/diluted share) vs $11.2M loss in Q1 2023 which included $62M one-time gain.
- Cash $331.4M at March 31, 2024; company expects funds to support operations into cash flow positivity.
- NDA resubmission for AXS-07 in migraine and NDA submission for AXS-14 in fibromyalgia targeted for Q2 2024.
- Positive Phase 3 SYMPHONY trial of AXS-12 in narcolepsy; Phase 3 ACCORD-2 for AXS-05 in Alzheimer's agitation initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024053197/0000950170-24-053197-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024053197/axsm-20240506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053197

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer